Brookline Capital Markets Estimates FBRX Q4 Earnings

Forte Biosciences, Inc. (NASDAQ:FBRX) – Investment analysts at Brookline Capital Markets issued their Q4 2026 earnings per share (EPS) estimates for shares of Forte Biosciences in a note issued to investors on Wednesday, May 13th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.90) per share for the quarter. The consensus estimate for Forte Biosciences’ current full-year earnings is ($4.63) per share.

Forte Biosciences (NASDAQ:FBRX) last posted its earnings results on Monday, May 11th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.08).

FBRX has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Forte Biosciences in a report on Friday, March 27th. Wall Street Zen downgraded shares of Forte Biosciences from a “sell” rating to a “strong sell” rating in a report on Sunday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $67.00.

Forte Biosciences Stock Up 1.5%

Shares of FBRX stock opened at $24.66 on Thursday. Forte Biosciences has a 12 month low of $6.70 and a 12 month high of $35.80. The company has a market cap of $342.53 million, a PE ratio of -5.31 and a beta of 3.01. The business’s 50 day moving average is $27.84 and its two-hundred day moving average is $25.44.

Hedge Funds Weigh In On Forte Biosciences

Several large investors have recently bought and sold shares of FBRX. Orbimed Advisors LLC boosted its holdings in Forte Biosciences by 101.8% in the 2nd quarter. Orbimed Advisors LLC now owns 1,196,955 shares of the company’s stock valued at $15,477,000 after purchasing an additional 603,867 shares during the period. Federated Hermes Inc. increased its holdings in shares of Forte Biosciences by 52.5% during the 3rd quarter. Federated Hermes Inc. now owns 1,635,380 shares of the company’s stock worth $24,531,000 after purchasing an additional 563,147 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of Forte Biosciences during the second quarter valued at about $4,310,000. Cable Car Capital LP raised its position in shares of Forte Biosciences by 127.7% during the second quarter. Cable Car Capital LP now owns 500,000 shares of the company’s stock valued at $6,465,000 after buying an additional 280,396 shares during the last quarter. Finally, Jain Global LLC bought a new stake in shares of Forte Biosciences in the fourth quarter valued at about $5,520,000. 77.63% of the stock is currently owned by institutional investors and hedge funds.

Forte Biosciences Company Profile

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.